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Abstract
Purpose The aim of this study was to identify the most appropriate measure of quality of life (QoL) for patients living with and
beyond cancer.
Methods One hundred eighty-two people attending cancer clinics in Central London at various stages post-treatment, completed
a series of QoL measures: FACT-G, EORTC QLQ-C30 , IOCv2 (positive and negative subscales) and WEMWBS, a wellbeing
measure. These measures were chosen as the commonest measures used in previous research. Correlation tests were used to
assess the association between scales. Participants were also asked about pertinence and ease of completion.
Results There was a significant positive correlation between the four domain scores of the two health-related QoL measures (.32
≤ r ≤ .72,P < .001), and a significant large negative correlation between these and the negative IOCv2 subscale scores (− .39 ≤ r ≤
− .63,P < .001). There was a significant moderate positive correlation between positive IOCv2 subscale andWEMWBS scores (r
= .35, P < .001). However, neither the FACT-G nor the EORTC showed any significant correlation with the positive IOCv2
subscale. Participants rated all measures similarly with regards to pertinence and ease of use.
Conclusion There was little to choose between FACT-G, EORTC, and the negative IOC scales, any of which may be used to
measure QoL. However, the two IOCv2 subscales capture unique aspects of QoL compared to the other measures. The IOCv2
can be used to identify those cancer survivors who would benefit from interventions to improve their QoL and to target specific
needs thereby providing more holistic and personalised care beyond cancer treatment.
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Introduction
By 2015, there were an estimated 2.5 million people in the UK
previously diagnosed with cancer [1], and rates continue to rise
with prediction of increasing survival rates for most cancers [2,
3]. It is projected that there will be 4 million people living with
or beyond cancer by 2030 [4]. As treatments and survival con-
tinue to improve, cancer now represents a chronic life-altering
condition, and quality of life (QoL) is increasingly recognised as
an important treatment outcome for those living with cancer [5,
6]. Depending on the type of cancer, survivors can experience a
variety of adverse and late physical effects of cancer therapy,
such as fatigue, pain and disability. However, survivors them-
selves have identified social and psychological problems (in-
cluding depression, anxiety, and fear of recurrence) as important
determinants of their QoL [7]. Studies have also shown that such
psychosocial factors are more highly associated with QoL than
the type and extent of the cancer. Although these problems are
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clearly prioritised by cancer patients [8], they still receive com-
paratively less attention in clinical care and research. A 2019
British study of 526 colorectal cancer survivors found that un-
met psychological needs were the highest of all unmet needs
following treatment [9]. These psychological unmet needs in-
cluded feelings of sadness, loss of control, fear of cancer recur-
rence and death, uncertainty, and difficulty in keeping a positive
outlook. Notably, the percentage of patients with psychological
unmet needs, 15 months after treatment, remained consistent
when measured again at 24 months. These unmet needs, in
addition to physical, health system, and informational needs,
were associated with poorer health-related quality of life at the
end of treatment. Therefore, it is potentially possible to identify
‘at risk’ patients as soon as they have finished treatment [9].
Defining and measuring the QoL of people living with and
beyond cancer is not straightforward. There are several well
validated and widely usedmeasures of health-relatedQoL, but
these focus predominantly on physical symptoms (rather than
psychosocial issues) related to the functional effects of being
treated for cancer, and often include specific symptoms such
as shortness of breath or disabilities such as problemswalking.
Such symptoms can also be related to other comorbid condi-
tions and, in a recent study, Vissers and colleagues [10]
showed that medical comorbidity explained more variance
in health-related QoL than did cancer characteristics.
Furthermore, the study of cancer survivorship abounds with
studies examining primarily negative outcomes such as dis-
tress, diminished QoL and functional impairments; less is
known about positive changes following the experience of
cancer. A more contemporary approach to the study of QoL
acknowledges the multidimensional and dynamic impact of
cancer whereby the experience of cancer can be life changing
in both negative and positive ways [11].
The Impact of Cancer (IOCv2) questionnaire was specifi-
cally developed to measure not only the unique negative im-
pacts of cancer, such as worry and body change concerns, but
also the positive impact of cancer associated with long-term
survivorship, such as increased altruism and positive self-
evaluation [12]. This measure has been used in studies of breast
and lymphoma cancer survivors in the USA and Europe
[13–16]. In our 2014 study of British haematological cancer
survivors [7], we found that levels of depression and psycho-
logical distress in this survivor group were three times higher
than in the general population, and these symptoms were sig-
nificantly associated with more negative IOCv2 scores. On the
other hand, the type and stage of the cancer, or whether there
had been a recurrence of the cancer, had no relationship to
IOCv2 scores. Positive IOCv2 scores showed a distinctive pat-
tern of association that reflected factors such as level of educa-
tion and social support. The IOC was originally developed for
long-term survivors (> 2 years after diagnosis); however, many
of the issues addressed in this measure are also experienced by
those at earlier stages in the cancer pathway.
Two of the most commonly used cancer-specific health-re-
lated QoLmeasures are the European Organisation for Research
and Treatment for Cancer Quality of Life Questionnaire Core 30
(EORTC QLQ-C30) [17], and the Functional Assessment of
Cancer Therapy—General Scale (FACT-G) [18]. These instru-
ments are usually combined with questionnaires assessing the
impact of the specific type of cancer. Although both measures
have high validity and reliability, they have been shown to have
different applications [19]. For instance, the EORTC focuses
more on disease symptoms and consequences of treatment,
whereas the FACT-G is more advantageous at assessing emo-
tional aspects. Nevertheless, these questionnaires may not ad-
dress some of themore subtle aspects of QoL identified by those
living with and beyond cancer as they were designed to focus
primarily on the early stages of being diagnosedwith and treated
for cancer [20]. As patients move towards the survivorship
phase, although certain functional and physical impairments re-
main, other issues may become equally or more relevant.
Therefore, these instruments may not adequately capture the
unique needs of longer-term cancer survivors.
The IOC was originally developed using qualitative meth-
odology to explore the constructs of both negative and posi-
tive impacts of cancer. Interviews were carried out with a
sample of patients who had survived cancer for 5 or more
years, but were entirely based in Los Angeles, USA [12].
While a proportion of participants were non-White, there
was no information about the ethnicities involved. It was un-
clear how useful instruments like the IOCv2 were when used
by British patients, and with more ethnically mixed groups of
patients in the UK, until a 2017 study compared the use of
IOCv2 in non-Hodgkin lymphoma (NHL) survivors in USA
and UK populations. Good reliability of the IOCv2 was
found, and so it was deemed potentially applicable to UK
populations [21]. In addition, this study demonstrated that
psychosocial factors had a greater impact on QoL than disease
characteristics [21]. With the increasing focus on how to im-
prove QoL for patients, an appropriate outcome measure is a
priority for research. Better conceptualization of QoL for peo-
ple living with and beyond cancer, and identification of useful
measures that reflect UK patients’ realities, needs, and percep-
tions have become pressing.
The specific objectives of this study were to compare com-
monly used QoLmeasures (FACT-G and EORTCQLQ-C30)
across corresponding domains (physical, emotional, social
and functional); as well as to the IOCv2 scale (positive and
negative subscales) and to an overall wellbeing measure
(WEMWBS) in different populations of cancer patients who
had completed active treatment. We did not seek correlations
against the EORTC QLQ-C30 cognitive functioning sub-
scale, since there was no equivalent domain in the FACT-G
questionnaire. The aim was to determine the optimal method
to identify and measure QoL in cancer patients living with and
beyond cancer. The hypotheses under test were:
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i. Corresponding domains in FACT-G and EORTC QLQ-
C30 are positively correlated and there is a negative cor-
relation with negative (–ve) IOCv2 as well as a positive
correlation with WEMWBS.
ii. FACT-G and EORTC QLQ-C30 do not correlate with
positive (+ve) IOCv2.
Methods
This study was carried out as a clinical audit (“Audit of well-
being/quality of life measures in cancer survivors” ID:
5711(2015) Barts Health NHS Trust) in oncology outpatient
clinics throughout Barts Health NHS Trust. A clinical audit
aims to evaluate the quality of current practice regarding a
specific aspect of healthcare and to identify any changes need-
ed in order to improve the care provided to patients. Therefore,
research projects and clinical audit projects serve different
purposes with the latter forming part of the continuous quality
improvement process [22].
Inclusion and exclusion criteria
Patients were eligible if they had finished active treatment for
cancer and were over the age of 18. Patients were excluded if
they were not able to speak English or if they were receiving
palliative care. Patients attending cancer clinics in central
London were screened against the eligibility criteria by a
member of the clinical care team. Eligible patients were then
approached at the clinic by a research assistant who invited
them to complete a series of questionnaires and provided them
with the study information sheet. No financial incentives or
any other forms of compensation were used. The clinics
attended were breast, head and neck, colorectal and
haematology-oncology (late effects and chronic myeloid leu-
kaemia (CML), myeloma, and the leukaemia and lymphoma
clinics).
Measures
FACT-G is a 27-item generic HRQL measure that has been
widely validated [18]. Each item has 5 options ranging from
not at all (a score of 0) to very much (a score of 4), and these
are summed to obtain a global score, as well as 4 subscale
scores: physical well-being, social/family well-being, emo-
tional well-being, and functional well-being. A higher score
signifies better QoL.
EORTC QLQ-C30 is a 30-item cancer-specific HRQL
measure that has also been widely validated [23]. Two items
ask about overall QoL and overall health, and the remainder
covers 5 functioning scales (physical, role, social, emotional,
and cognitive functioning) and 9 symptoms scales (fatigue,
nausea and vomiting, pain, dyspnea, sleep disturbance, appe-
tite loss, constipation, diarrhoea, and financial impact). A
higher score for the global QoL or the functioning scales sig-
nifies better QoL.
Warwick–Edinburgh Wellbeing Scale (WEMWBS) [24]
measures a broad concept of mental wellbeing, including pos-
itive affect, psychological functioning (autonomy, compe-
tence, self-acceptance, personal growth), and interpersonal re-
lationships. A higher score signifies better QoL. The
WEMWBS was chosen as it focuses on positive aspects of
mental health, it is valid in a range of settings and it can be
used at a population level or with targeted clinical groups.
Furthermore, it is relatively short and easy to complete com-
pared to the other measures included in this study.
Impact of Cancer V2 (IOCv2) is a 37-item shortened ver-
sion of the IOC [25]. The IOCv2 measures the unique positive
and negative impacts of cancer associated with long-term sur-
vivorship. Participants rate their level of agreement for a given
statement from 1 (strongly disagree) to 5 (strongly agree),
which results in both a positive and negative scale. The scales
are subdivided into eight subscales. The four positive sub-
scales include: Altruism/Empathy, Health Awareness,
Meaning of Cancer and Positive Self-Evaluation; a higher
score signifies better QoL. The negative subscales include
Appearance Concerns, Body Change Concerns, Life
Interferences and Worry. A higher score signifies worse QoL.
In addition, patients were asked to rate each questionnaire
on a 5-point Likert scale with regards to (a) how much it
addressed their issues and (b) how easy it was to complete.
Sociodemographic data were also collected.
Statistical analysis
Data were analysed using statistical software package SPSS
version 24. Missing data were not imputed. Spearman’s rank
correlation was used as the data were not normally distributed.
One-tailed tests were used to predict correlation across the
questionnaires according with our one-directional hypotheses.
A P value of less than 0.01 was considered statistically signif-
icant. We chose this conservative P value due to the presence
of multiplicity. The medians (interquartile range) of Likert
score responses to the two questions about pertinence and ease
of completion were calculated. Friedman’s test was used to
detect any statistically significant differences in the pertinence
and ease of completion ratings between the four different
measures. Cronbach’s alpha was calculated for each measure
in the study in order to assess internal consistency. Further
analysis was conducted to compare QoL scores for each mea-
sure according to cancer diagnosis using Kruskal-Wallis test
with Dunn’s post hoc test. Alpha coefficient values suggested
that all measures were fit for purpose (IOC positive α = 0.85;
IOC negative α = 0.89; WEMWBS α = 0.93; FACT-G α =
0.92; EORTC QLQ-C30 α = 0.88).
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Results
Of the 317 patients who were approached, 182 agreed to par-
ticipate in the audit. Therefore, the response rate was 57%.
Reasons were recorded for those who declined to take part.
Language barriers and lack of time were the most commonly
cited issues. In this audit, information was available only on
gender and cancer type. Figure 1 shows the completers vs
non-completers by cancer type.
There was no significant difference in gender between
completers and non-completers. However, those with head
and neck cancer were more likely to decline to take part.
The demographics of participants are shown in Table 1:
57% of participants were women and 77% of participants
were white. Age ranged from 18 to > 75 years.
Table 2 shows the correlations between scores on the dif-
ferent measures. As hypothesised, QLQ-C30 and FACT-G
significantly positively correlated with each other across cor-
responding domains: physical, social, emotional, and func-
tional respectively (.32 ≤ r ≤ .72, P < .001). The strongest
correlation was between the physical sub-scales of the two
questionnaires (r = .74, P < .001), whereas the association
between the social sub-scales was the weakest (r = .32, P <
.001). Furthermore, each domain of both measures was sig-
nificantly negatively correlated with negative IOC (− .39 ≤ r ≤
− .63, P < .001), i.e. high negative impact was correlated with
poorer QoL. The social and emotional domains of the EORTC
QLQ-C30 were most strongly correlated with negative IOC (r
= − .57, P < .001 for both), whereas regarding the FACT-G,
the strongest correlation with negative IOC was for the phys-
ical domain (r = − .63, P < .001). The IOC positive measure
generally did not correlate across any of the QoL measures.
There was a significant moderately positive correlation be-
tween WEMWBS and positive IOC scores (r = .35, P <
.001). Regarding correlations between total scores, the stron-
gest correlations were between the FACT-G and the Global
QoL of the EORT QLQ-C30 (r = .76, P < .001), as well as
between FACT-G and WEMWBS total scores (r = .72, P <
.001). There were no statistically significant correlations be-
tween the IOC positive scale score and other total scores ex-
cept for the aforementioned positive correlation with




Breast N = 51
Colo-rectal N = 22
Head & Neck N = 27
Hematology N = 82 
Total N = 182
NO
Breast N = 35
Colo-rectal N = 11
Head & Neck N = 48
Hematology N = 41 
Total N = 135
Fig. 1 Cancer types of completers vs non-completers
Table 1 Socio-demographic characteristics of participants in the audit
(N = 182)
Characteristics Frequency Percent














Gender (N = 180, missing = 2)
Male 77 42.8
Female 103 57.2




Haematology–late effects 27 -
Haematology–lymphoma 9 -
Haematology–multiple myeloma 21 -
Head and neck 27 -
Education level (n = 156, missing = 26)
Degree 51 32.7
Technical qualification 22 14.1
A levels or equivalent 18 11.5
GCSE’s, O’ levels or equivalent 46 29.5
Other 19 12.2




with both the FACT-G total score (r = − .70, P < .001) and
with the Global QoL score of the EORTC QLQ-C30 (r = −
.54, P < .001).
There was no evidence of a significant difference in QoL
scores among the cancer groups at the considered 1% level of
significance. However, at the conventional 5% level of















2a: Association of the physical domains






.04,140, .333 1, 150, –
WEMWBS total score .35, 146, < .001 − .52, 147, < .001 1, 174, –
EORTC QLQ-C30 − .007, 148, .468 − .44, 148, < .001 .39, 170, <
.001
1,177,-












.04,140, .333 1, 150, –
WEMWBS total score .35, 146, < .001 –.52, 147, < .001 1, 174, –
EORTC QLQ-C30 .01, 146, .442 − .57, 146, < .001 .44, 167, <
.001
1, 174, -





2c: Association of the emotional domains






.04,140, .333 1, 150, –
WEMWBS total score .35, 146, < .001 − .52, 147, < .001 1, 174, –
EORTC QLQ-C30 .29, 147, .366 -.57, 147, <.001 .52, 169,
<.001
1, 176, -





2d: Association of the functional domains






.04,140, .333 1, 150, –
WEMWBS total score .35, 146, < .001 − .52, 147, < .001 1, 174, -
EORTC QLQ-C30 .01, 148, .436 − .39, 147, < .001 .39, 170, <
.001
1, 176, –










.04,140, .666 1, 150, –
WEMWBS total score .35, 146, < .001 − .52, 147, < .001 1, 174, -
EORTC QLQ-C30
Global QoL score










Note. r Spearman’s rank correlation coefficient, n sample size, IOC impact of cancer,WEMWBSWarwick-Edinburgh Mental Wellbeing Scale, EORTC
QLQ-C30 European Organisation for Research and Treatment of Cancer–Quality of Life Questionnaire, FACT-G Functional Assessment of Cancer
Therapy–General
a Correlations between total scores are significant at the 0.05 level (two-tailed)
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significance, EORTC Global QoL scale score may be consid-
ered differed among the cancer groups (Table 3). A Kruskal-
Wallis test showed there was a significant difference (P =
.043) between at least one pair of groups. Dunn’s pairwise
tests confirmed (adjusted using the Bonferroni correction) that
the significant difference (P = .028) was between breast and
colorectal patients.
The median scores and the interquartile range of the two
additional questions regarding pertinence and ease of comple-
tion can be seen in Table 4. Scores were similar for all the
questionnaires with the FACT-G scoring the highest on the
ease of completion question. Nevertheless, a Friedman test
indicated the four scales were not rated significantly different-
ly on either question (pertinence: χ2 (3) = 0.63, P = 0.89; ease
of completion: χ2 (3) = 3.99, P = 0.26).
Discussion
In this study of patients attending a range of cancer clinics in
London, we compared two widely used QoL measures
(FACT-G and EORTC QLQ-C30) and a general wellbeing
scale (WEMWBS) with the IOC scale, designed specifically
for cancer survivors to address both negative and positive
aspects of living with and beyond cancer.
There were positive correlations between the two health-
related QoL subscale measures of the same domains (physical,
social, emotional, and functional of FACT-G and EORTC
QLQ-C30), as well as between the total FACT-G score and
the Global QoL subscale score of the EORTC QLQ-C30. As
hypothesised, a negative correlation between the two health-
related QoL measures and the negative IOC scale was also
observed. There was also a positive correlation between pos-
itive IOC and the WEMWBS general wellbeing measure;
though WEMWBS is not specifically applicable to partici-
pants’ cancer experience. Neither the FACT-G nor the
EORTC QLQ-C30 showed any correlation with the positive
IOC scale, suggesting that the positive IOC scale measures
something different from health-related QoL. Finally, of the
QoL measures used in this audit, the participants reported
similar ease of completion and preference for all the scales.
The analyses show that the IOC positive scores did
not correlate with, and, therefore, were not covered by
any of the other QoL measures, except for a moderate
correlation with the WEMWBS scale, which was to be
expected as that scale too focuses on positive aspects of
general well-being. The IOC is therefore not only highly
relevant to cancer patients in a central London clinic, but
also unique amongst other scales in addressing the more
positive aspects of perceived QoL in the post-treatment
phase.
There is evidence that positive IOC is not merely the
obverse of negative IOC, but represents different con-
structs of cancer survivors’ experience that translate across
different countries and contexts [21]. Positive IOC may
reflect a less understood area of cancer enquiry: that some
patients, for reasons which are not entirely clear, are able to
educe positive experiences from a significant and stressful
life event such as being diagnosed with and treated for
cancer.
Importantly, this ability may be a skill that could be ac-
quired and there are promising therapies available such as
Acceptance Commitment Therapy (ACT), which focus on
helping patients to re-engage with what matters to them the
most, thus promoting a values-based living while at the same
time working on acceptance of things that are not within one’s
control. Although a higher positive IOC score may not neces-
sarily translate into a better functional level, people living with
cancer might experience a better QoL, which is an important
outcome. A 2015 study showed that both positive and nega-
tive perceptions of the impact of cancer are independent me-
diators of QoL [13]. Future studies could examine the effec-
tiveness of using ACT and other supportive interventions to
promote positive cancer outcomes for patients in the survivor-
ship phase, as well as for patients under active treatment
whenever possible.
Table 3 Total QoL scores for five
scales according to cancer
diagnosis
IOC positive IOC negative WEMWBS EORTC FACT-G
Median Median Median Median Median
Breast 59 57 51 66.7 12.6
Colorectal 59 50 55 83.3 13.4
Head and neck 62 50 53 75 13.5













Note: IOC impact of cancer, WEMWBS Warwick-Edinburgh Mental Wellbeing Scale, EORTC QLQ-C30
European Organization for Research and Treatment of Cancer–Quality of Life Questionnaire, FACT-G
Functional Assessment of Cancer Therapy-General
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Study limitations
A limitation of this study was the 57% participation in the
audit, which is consistent with response rates in similar studies
[21]. The reasons for non-participation of patients are instruc-
tive for future research, e.g. some patients felt overwhelmed
by the need to fill in questionnaires, some had problems with
literacy, and many did not have enough command of the
English language to participate. There was also a preponder-
ance of White British participants and thus these results may
not generalise to other groups. However, this also highlights
the need for a simple, quick, and easily understood question-
naire that can be used as an effective screening method.
Conclusion
Determining how best to measure QoL in people living with
and beyond cancer is of paramount importance to ensure the
best approach to screening and assessing the effectiveness of
interventions but also to ensure holistic care within clinics that
extends beyond cancer treatment. Our results suggest that both
the FACT-G and the EORTCQLQ-C30 are measuring similar
aspects of QoL and are equally pertinent and easy to use; so
either may be used. The current findings suggest that the IOC
captures a unique aspect of QoL over the other measures,
related to post-traumatic growth [26].
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